At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control
In Brief
A Phase 3 clinical trial evaluating Insulin Glargine 100 UNT/ML Pen Injector [Lantus], Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg, and 1 other intervention for Type2diabetes. Completed, enrolled 243 participants across 1 site.
Detailed Summary
In this study, we aim to explore the beneficial effect of early short-term (two weeks), self-titrated, basal-only insulin therapy on the degree of glycemic control over 1-year follow through a prospective cohort.
Study Details
Timeline
Interventions
Insulin is given as glargine U100 at bedtime in a dose of 10 units. The patients will be given instruction to up-titrate the insulin by adding two units every two days with an aim to reach fasting blood glucose (FBG) between 80 - 130 mg/dl using a home glucometer. And to down-titrate the insulin by subtracting two units when the FBG is below 80 mg/dl. The patients continued on basal insulin for two weeks or less when FBG is persistently below 100 mg/dl on a dose of 10 units of insulin Glargine.
Saxagliptin 2.5 mg/ Metformin Hydrochloride extended release 1000 mg
Pioglitazone 30mg